Medicus Pharma Highlights Skinject Breakthrough and Pipeline Growth in Oncology
Medicus Pharma (NASDAQ: MDCX) is advancing a non-invasive treatment for one of the most common cancers with its Skinject microneedle patch, currently in Phase 2 trials. The therapy is designed to treat lesions directly at the site, with data suggesting that up to 3 out of 4 patients may avoid immediate surgery, addressing a major treatment backlog affecting millions of patients.
Alongside Skinject, Medicus is progressing its broader pipeline, including Teverelix, targeting advanced prostate cancer with high cardiovascular risk. With upcoming FDA discussions, potential pivotal trials, and active partnering efforts, the company is positioning itself for continued growth in the biotech sector.
#MedicusPharma
#MDCX
#Biotech
#SkinCancer
#BasalCellCarcinoma
#ClinicalTrials
#Oncology
#ProstateCancer
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#BiotechInvesting
#LifeSciences
#NewsOut
